Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS) who are
considered eligible for reduced intensity conditioning allogeneic stem cell transplant by the
transplant team at WCI (Wilmot Cancer Institute)will be enrolled in the study. Patients will
receive Fludarabine starting day -6 and Melphalan on day -2 and HBO (Hyperbaric Oxygen)
therapy on day 0 of the transplant. Subjects will be followed for any toxicity related to
therapy. After neutrophil recovery is documented, the patients will be seen in clinic at
least weekly through day +100.